Cargando…

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

PURPOSE: Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chasen, Martin, Urban, Laszlo, Schnadig, Ian, Rapoport, Bernardo, Powers, Dan, Arora, Sujata, Navari, Rudolph, Schwartzberg, Lee, Gridelli, Cesare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127871/ https://www.ncbi.nlm.nih.gov/pubmed/27557833 http://dx.doi.org/10.1007/s00520-016-3388-7

Ejemplares similares

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018)

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
por: Rapoport, Bernardo Leon, et al.
Publicado: (2017)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
por: Rapoport, Bernardo Leon
Publicado: (2017)

Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy
por: Navari, Rudolph M, et al.
Publicado: (2019)

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
por: Barbour, S., et al.
Publicado: (2017)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
por: Lee, So Rae, et al.
Publicado: (2020)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
por: Weinstein, Cindy, et al.
Publicado: (2020)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
por: Schnadig, Ian D, et al.
Publicado: (2017)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
por: Hu, Zhihuang, et al.
Publicado: (2016)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent
por: Solanki, Sohel, et al.
Publicado: (2022)

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
por: Navari, Rudolph M, et al.
Publicado: (2023)

Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy
por: Toda, Haruka, et al.
Publicado: (2017)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)
por: Weinstein, C., et al.
Publicado: (2016)

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
por: Vardy, J, et al.
Publicado: (2006)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
por: Yoshida, Naohisa, et al.
Publicado: (2019)

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
por: Tanioka, M, et al.
Publicado: (2013)

Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
por: Wu, Xuan, et al.
Publicado: (2020)

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
por: Abe, Masakazu, et al.
Publicado: (2015)

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
por: Gabrail, Nashat, et al.
Publicado: (2015)

One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis
por: Watanabe, Daichi, et al.
Publicado: (2022)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
por: Aapro, M., et al.
Publicado: (2014)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
por: Willier, Semjon, et al.
Publicado: (2019)

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
por: Sigsgaard, T, et al.
Publicado: (1999)

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
por: Boccia, Ralph, et al.
Publicado: (2016)

Safety of Polysorbate 80 in the Oncology Setting
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
por: Vo, Thao T., et al.
Publicado: (2012)

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
por: Celio, Luigi, et al.
Publicado: (2019)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gd86ncctjsbsho81emrqi0gdlr